These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1742076)

  • 1. Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children.
    Wiseman G; Rubinstein A; Martinez P; Lambert S; Devash Y; Goldstein H
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):839-45. PubMed ID: 1742076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternofetal transmission of human immunodeficiency virus-1: the role of antibodies to the V3 primary neutralizing domain.
    Rubinstein A; Goldstein H; Calvelli T; Devash Y; Rubinstein R; Soeiro R; Lyman W
    Pediatr Res; 1993 Jan; 33(1 Suppl):S76-8; discussion S78-9. PubMed ID: 8433879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing, MN-like PND-directed antibodies in Rwandan children with long-term HIV1 infection.
    Fraisier C; Van de Perre P; Lepage P; Hitimana DG; Karita E; Desgranges C
    Res Virol; 1995; 146(3):201-10. PubMed ID: 7481092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
    AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of titer of antibody to principal neutralizing domain of HIVMN strain with disease progression in Japanese hemophiliacs seropositive for HIV type 1.
    Yamanaka T; Fujimura Y; Ishimoto S; Yoshioka A; Konishi M; Narita N; Mimaya J; Meguro T; Nakasone T; Okamoto Y; Yoshizaki H; Yamada K; Honda M
    AIDS Res Hum Retroviruses; 1997 Mar; 13(4):317-26. PubMed ID: 9071431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.
    Devash Y; Calvelli TA; Wood DG; Reagan KJ; Rubinstein A
    Proc Natl Acad Sci U S A; 1990 May; 87(9):3445-9. PubMed ID: 2333294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB.
    Nehete PN; Murthy KK; Satterfield WC; Arlinghaus RB; Sastry KJ
    AIDS; 1995 Jun; 9(6):567-72. PubMed ID: 7662194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.
    Zwart G; Langedijk H; van der Hoek L; de Jong JJ; Wolfs TF; Ramautarsing C; Bakker M; de Ronde A; Goudsmit J
    Virology; 1991 Apr; 181(2):481-9. PubMed ID: 2014634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
    Devash Y; Rusche JR; Nara PL
    Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
    Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
    AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
    Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
    Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.